Key Dates

Related Announcements

NOT-OD-20-123 - Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic

NOT-OD-20-163 - Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic

PAR-20-084 - NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)

Issued by

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Purpose

The purpose of this Notice is to inform applicants to the NIBIB R21 Trailblazer, PAR-20-084, that the Special Exception to Post-Submission of preliminary data during the COVID-19 Pandemic will not apply to applications submitted to PAR-20-084.

A distinct feature for the Trailblazer FOA is that no preliminary data are required, expected, or encouraged, however, if available, minimal preliminary data, limited to one-half page, are allowed only in the original submission. Trailblazer approaches are expected to differ substantially from current thinking or practice, therefore, extensive preliminary data demonstrating feasibility is an indication that the project is beyond the scope of the FOA. Due to the special preliminary data limitations for applications submitted to the Trailblazer Funding Opportunity Announcement (PAR-20-084), post submission of preliminary data will not be allowed for NIBIB Trailblazer applications.

Inquiries

Please direct all inquiries to:

Randy King, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Telephone: 301-451-0707
Email: [email protected]